Health Care·Biotechnology·$5.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | -18.93% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.49 | N/A | -18.93% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions affecting performance. They reiterated their commitment to strategic initiatives.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Immunovant's Q3 results show a significant loss per share, which was worse than expected. The stock dropped nearly 3% in response, reflecting investor concerns about the company's financial health and lack of revenue updates. The absence of guidance adds to uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CATERPILLAR INC
Jan 31, 2023